Literature DB >> 8702032

Comparability of treatment groups and risk factors for parasitemia at the first antenatal clinic visit in a study of malaria treatment and prevention in pregnancy in rural Malawi.

R W Steketee1, J J Wirima, L Slutsker, J G Breman, D L Heymann.   

Abstract

The problems of Plasmodium falciparum infection in pregnant women have been described in numerous sub-Saharan African countries, but the frequency of parasitemia at the first antenatal visit and risk factors for infection have not been fully investigated. During a prospective antimalarial treatment and prophylaxis trial in pregnant women in Malawi (three groups receiving a chloroquine regimen and one group receiving a mefloquine regimen), we examined women at their first antenatal clinic visit to evaluate these issues and to verify that subjects in the study treatment/prevention arms were similar. Among 4,127 women with enrollment blood smear results, 1,836 (44.5%) were parasitemic. The highest infection rates and densities were observed in primigravidas (66% infected, geometric mean parasite density [GMPD] = 1,588 parasites/mm3 of whole blood), followed by second pregnancies (46% infected, GMPD = 615 parasites/mm3) and subsequent pregnancies (29% infected, GMPD = 238 parasites/mm3), (P < 10(-6) for both infection prevalence and density, by chi-square test for trend). Significant risk factors for parasitemia at first antenatal clinic visit in a multivariate model included low gravidity, high transmission season, no use of prophylaxis before first antenatal clinic visit, young age (< 20 years), human immunodeficiency virus (HIV) infection, low hematocrit, short stature, and second trimester (compared with third trimester). Women in the different treatment arms of the study were generally similar in many characteristics; statistically significant differences, where present, were small. Targeting malaria control efforts to women in their first or second pregnancy and during the high transmission season will be an important strategy to reach most parasitemic women and minimize resource expenditure. Women infected with HIV had a 55% increased risk of parasitemia at their first antenatal clinic visit and may represent an additional important risk group whose numbers may be increasing and who may benefit from identification and management for malaria.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8702032     DOI: 10.4269/ajtmh.1996.55.17

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  23 in total

1.  The Interaction between HIV and malaria in Africa.

Authors:  Miriam K Laufer; Christopher V Plowe
Journal:  Curr Infect Dis Rep       Date:  2007-01       Impact factor: 3.725

2.  Maternal anthropometry and weight gain as risk factors for poor pregnancy outcomes in a rural area of southern Malawi.

Authors:  Bf Kalanda
Journal:  Malawi Med J       Date:  2007-12       Impact factor: 0.875

3.  Malaria and Human Immunodeficiency Virus Infection.

Authors:  S R Mehta; A J Swamy; J Muthukrishnan; A K Malviya
Journal:  Med J Armed Forces India       Date:  2011-07-21

4.  Spontaneous postpartum clearance of Plasmodium falciparum parasitemia in pregnant women, Benin.

Authors:  Julie Bottero; Valérie Briand; Carine Agbowai; Justin Doritchamou; Achille Massougbodji; Michel Cot
Journal:  Am J Trop Med Hyg       Date:  2011-02       Impact factor: 2.345

5.  Update on the efficacy, effectiveness and safety of artemether-lumefantrine combination therapy for treatment of uncomplicated malaria.

Authors:  Pauline Byakika-Kibwika; Mohammed Lamorde; Harriet Mayanja-Kizza; Concepta Merry; Bob Colebunders; Jean-Pierre Van Geertruyden
Journal:  Ther Clin Risk Manag       Date:  2010-02-02       Impact factor: 2.423

Review 6.  Drugs for treating uncomplicated malaria in pregnant women.

Authors:  Lois C Orton; Aika A A Omari
Journal:  Cochrane Database Syst Rev       Date:  2008-10-08

Review 7.  Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment.

Authors:  Denitsa Radeva-Petrova; Kassoum Kayentao; Feiko O ter Kuile; David Sinclair; Paul Garner
Journal:  Cochrane Database Syst Rev       Date:  2014-10-10

8.  Randomized trial of artesunate+amodiaquine, sulfadoxine-pyrimethamine+amodiaquine, chlorproguanal-dapsone and SP for malaria in pregnancy in Tanzania.

Authors:  Theonest K Mutabingwa; Kandi Muze; Rosalynn Ord; Marnie Briceño; Brian M Greenwood; Chris Drakeley; Christopher J M Whitty
Journal:  PLoS One       Date:  2009-04-08       Impact factor: 3.240

9.  Epidemiology and aetiology of maternal parasitic infections in low- and middle-income countries.

Authors:  Tom Roberts; Courtney A Gravett; Prasad Palani Velu; Evropi Theodoratou; Thor A Wagner; Jian Shayne F Zhang; Harry Campbell; Craig E Rubens; Michael G Gravett; Igor Rudan
Journal:  J Glob Health       Date:  2011-12       Impact factor: 4.413

10.  Effectiveness of two antifolate prophylactic strategies against malaria in HIV-positive pregnant women in Bangui, Central African Republic: study protocol for a randomized controlled trial (MACOMBA).

Authors:  Alexandre Manirakiza; Abdoulaye Sepou; Eugène Serdouma; Samuel Gondje; Ghislain Géraud Banthas Bata; Sandrine Moussa; Aude Boulay; Jean Methode Moyen; Olga Sakanga; Lenaig Le-Fouler; Mirdad Kazanji; Muriel Vray
Journal:  Trials       Date:  2013-08-14       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.